{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:10:16Z","timestamp":1777695016138,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Integr Cancer Ther"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>Background: Viscum album L (VA, mistletoe) extracts are commonly used in integrative oncology. Here the clinical safety profile of additional VA-treatments to standard care in cancer patients with preexisting autoimmune diseases was analyzed. Methods: In this observational cohort study medical data and recorded adverse events (AEs) of treated patients were retrieved from the Network Oncology registry and a safety analysis was performed. Results: A total of 106 patients (median age 63 years) treated with add-on VA-extracts were analyzed. Most frequent autoimmune diseases were Hashimoto\u2019s thyroiditis (27%), psoriasis (19%), and ulcerative colitis (15%). Seventeen patients (16%) experienced VA-related AEs, but neither long-term side effects nor VA-therapy discontinuations were recorded. In a subgroup of 30 patients receiving long-term VA-therapy no exacerbations or flares of underlying autoimmune diseases were recorded. Additionally, a significant halving of overall AE-rates was observed during VA-treatment periods (p= 0.019). Conclusions: Our findings suggest that add-on VA-therapy in cancer patients with preexisting autoimmune diseases as Hashimoto\u2019s thyroiditis, psoriasis, ulcerative colitis, Grave\u2019s disease, and some rheumatic diseases is safe. No higher rates of VA-associated AEs were observed and the overall AE-rates were significantly lowered in VA-therapy periods. However, results should be interpreted with caution in light of the study\u2019s observational character.<\/jats:p>","DOI":"10.1177\/1534735419832367","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T01:43:23Z","timestamp":1551231803000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Use and Safety of\n                    <i>Viscum album L<\/i>\n                    Applications in Cancer Patients With Preexisting Autoimmune Diseases: Findings From the Network Oncology Study"],"prefix":"10.1177","volume":"18","author":[{"given":"Shiao Li","family":"Oei","sequence":"first","affiliation":[{"name":"Research Institute Havelh\u00f6he, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Thronicke","sequence":"additional","affiliation":[{"name":"Research Institute Havelh\u00f6he, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kr\u00f6z","sequence":"additional","affiliation":[{"name":"Research Institute Havelh\u00f6he, Berlin, Germany"},{"name":"Institute for Social Medicine, Charit\u00e9, Berlin, Germany"},{"name":"Institute for Integrative Medicine, Witten\/Herdecke, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Matthes","sequence":"additional","affiliation":[{"name":"Research Institute Havelh\u00f6he, Berlin, Germany"},{"name":"Institute for Social Medicine, Charit\u00e9, Berlin, Germany"},{"name":"Medical Clinic for Gastroenterology, CBF, Charit\u00e9, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedemann","family":"Schad","sequence":"additional","affiliation":[{"name":"Research Institute Havelh\u00f6he, Berlin, Germany"},{"name":"Oncological Centre, Hospital Havelh\u00f6he, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"bibr1-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160221"},{"key":"bibr2-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.09.007"},{"key":"bibr3-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1177\/1534735411423920"},{"issue":"2","key":"bibr4-1534735419832367","author":"Horneber MA","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"bibr5-1534735419832367","first-page":"508","volume":"56","author":"Bussing A","year":"2006","journal-title":"Arzneimittelforschung"},{"key":"bibr6-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6882-11-72"},{"key":"bibr7-1534735419832367","first-page":"9","volume":"14","author":"Schink M","year":"2007","journal-title":"Forsch Komplementmed"},{"key":"bibr8-1534735419832367","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S145221"},{"issue":"1","key":"bibr9-1534735419832367","first-page":"523","volume":"28","author":"Beuth J","year":"2008","journal-title":"Anticancer Res"},{"key":"bibr10-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/219402"},{"key":"bibr11-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2010.06.013"},{"key":"bibr12-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1016\/j.explore.2012.06.005"},{"key":"bibr13-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/236310"},{"key":"bibr14-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/724258"},{"key":"bibr15-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1177\/1534735414563977"},{"key":"bibr16-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.07.022"},{"key":"bibr17-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr333"},{"key":"bibr18-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.2001.0442"},{"key":"bibr19-1534735419832367","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020377"},{"key":"bibr20-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2008.163"},{"key":"bibr21-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2006.12.004"},{"key":"bibr22-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4372"},{"key":"bibr23-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000286"},{"key":"bibr24-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1810-0"},{"key":"bibr25-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918764628"},{"key":"bibr26-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1159\/000356204"},{"key":"bibr27-1534735419832367","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed February 13, 2019."},{"key":"bibr28-1534735419832367","unstructured":"R Foundation. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2016. https:\/\/www.R-project.org\/"},{"key":"bibr29-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2017.09.004"},{"key":"bibr30-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6882-11-116"},{"key":"bibr31-1534735419832367","first-page":"1893","volume":"28","author":"Bussing A","year":"2008","journal-title":"Anticancer Res"},{"key":"bibr32-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1177\/0192623316677327"},{"key":"bibr33-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0494-6"},{"key":"bibr34-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4628287"},{"key":"bibr35-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1159\/000453265"},{"key":"bibr36-1534735419832367","first-page":"456","volume":"54","author":"Bock PR","year":"2004","journal-title":"Arzneimittelforschung"},{"key":"bibr37-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.010"},{"key":"bibr38-1534735419832367","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-017-2045-0"}],"container-title":["Integrative Cancer Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1534735419832367","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1534735419832367","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1534735419832367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:16:27Z","timestamp":1777454187000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1534735419832367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":38,"alternative-id":["10.1177\/1534735419832367"],"URL":"https:\/\/doi.org\/10.1177\/1534735419832367","relation":{},"ISSN":["1534-7354","1552-695X"],"issn-type":[{"value":"1534-7354","type":"print"},{"value":"1552-695X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"article-number":"1534735419832367"}}